(-)-3-(3,4-dimethoxyphenyl)-6-[(5,6-dimethoxyphenethyl)methylamino]hexane-3-carbonitrile
| Title | Journal |
|---|---|
| Verapamil stereoisomers induce antiproliferative effects in vascular smooth muscle cells via autophagy. | Toxicology and applied pharmacology 20120801 |
| Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics. | PloS one 20120101 |
| An overview of the evidence and mechanisms of herb-drug interactions. | Frontiers in pharmacology 20120101 |
| Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110614 |
| Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. | Drug metabolism and disposition: the biological fate of chemicals 20110301 |
| Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. | Journal of clinical pharmacology 20110201 |
| A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. | Clinical pharmacokinetics 20110201 |
| Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations. | Philosophical transactions. Series A, Mathematical, physical, and engineering sciences 20100628 |
| The synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperda (Sf9) insect cells. | Talanta 20100615 |
| Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of (14)C-labeled R- and S-verapamil in plasma. | Bioanalysis 20100301 |
| Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. | PloS one 20100101 |
| Stereoselective Inhibition of the hERG1 Potassium Channel. | Frontiers in pharmacology 20100101 |
| The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. | Basic & clinical pharmacology & toxicology 20090701 |
| Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1. | Molecular vision 20090101 |
| Studies of verapamil binding to human serum albumin by high-performance affinity chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081201 |
| Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. | Canadian journal of physiology and pharmacology 20080501 |
| Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. | Clinical pharmacology and therapeutics 20071101 |
| (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. | The Journal of biological chemistry 20071026 |
| Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. | European journal of clinical pharmacology 20060801 |
| Chiral capillary electrophoretic analysis of verapamil metabolism by cytochrome P450 3A4. | Journal of chromatography. A 20060707 |
| The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. | Clinical pharmacology and therapeutics 20060301 |
| Monitoring of verapamil enantiomers concentration in overdose. | Clinical toxicology (Philadelphia, Pa.) 20060101 |
| Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. | Current drug metabolism 20051001 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. | International journal of clinical pharmacology and therapeutics 20050401 |
| ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. | Cancer cell international 20050101 |
| Actions of R- and S-verapamil and nifedipine on rat vascular and intestinal smooth muscle. | Autonomic & autacoid pharmacology 20040701 |
| St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. | Clinical pharmacology and therapeutics 20040401 |
| Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. | Drug metabolism and disposition: the biological fate of chemicals 20040201 |
| Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. | Drug metabolism and disposition: the biological fate of chemicals 20040201 |
| (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. | Nuclear medicine and biology 20031001 |
| Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20030501 |
| Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. | Anti-cancer drugs 20030201 |
| Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). | Journal of medicinal chemistry 20021219 |
| Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. | Biopharmaceutics & drug disposition 20020101 |
| Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. | Clinical pharmacology and therapeutics 20010501 |